About the Company

CoLucid Pharmaceuticals (NasdaqGM: CLCD) is a clinical-stage biotechnology company that is developing lasmiditan to address an unmet medical need for acute migraine therapies. The Company is positioning the drug as a first-line therapy for individuals who are contraindicated from using triptans, the current standard-of-care, or as a second-line therapy for those who do not respond to triptans. CoLucid is currently evaluating lasmiditan in a Phase III trial under a Special Protocol Assessment (SPA) agreement with the FDA and expects to report results in the third quarter of 2016.

Source: LifeSci Capital, LLC research report

Research analyst certification and important disclosures can be found in the full research report. To access the full research report, please click on the link below.

Recent Research